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Abstract: We investigated the ionization profiles for open-ring (OR) and closed-ring (CR) 
forms of midazolam and drug-binding modes with heptakis-(2,3,6-tri-O-methyl)-β-
cyclodextrin (trimethyl-β-cyclodextrin; TRIMEB) using molecular modeling techniques and 
quantum mechanics methods. The results indicated that the total net charges for different 
molecular forms of midazolam tend to be cationic for OR and neutral for CR at physiological 
pH levels. The thermodynamic calculations demonstrated that CR is less water-soluble than 
OR, mainly due to the maximal solvation energy (߂ܩ௦௢௟௩஼ோ  = −9.98 kcal·mol−1), which has a 
minimal ߂ܩ௦௢௟௩ைோ 	of −67.01 kcal·mol−1. A cell viability assay did not detect any signs of 
TRIMEB and OR/CR-TRIMEB complex toxicity on the cEND cells after 24 h of 
incubation in either Dulbecco’s Modified Eagles Medium or in heat-inactivated human 
serum. The molecular docking studies identified the more flexible OR form of midazolam 
as being a better binder to TRIMEB with the fluorophenyl ring introduced inside the 
amphiphilic cavity of the host molecule. The OR binding affinity was confirmed by a 
minimal Gibbs free energy of binding (߂ܩ௕௜௡ௗ ) value of −5.57 ± 0.02 kcal·mol−1, an 
equilibrium binding constant (ܭ௕) of 79.89 ± 2.706 μM, and a ligand efficiency index 
(ܮܧ௟௜௚) of −0.21 ± 0.001. Our current data suggest that in order to improve the clinical 
applications of midazolam via its complexation with trimethyl-β-cyclodextrin to increase 
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drug’s overall aqueous solubility, it is important to concern the different forms and ionization 
states of this anesthetic. All mean values are indicated with their standard deviations. 
Keywords: trimethyl-β-cyclodextrin; midazolam; transition state; molecular docking; 
Gibbs free energy of binding; quantum mechanics; free energy of solvation; torsional energy 
 
1. Introduction 
Complexation mechanisms of drug-like chemical compounds with different cyclodextrins (CD) to 
establish a host-guest complex in solution, result in the improvement of pharmacokinetic parameters 
and physicochemical properties of the guest component, such as higher stability, increased aqueous 
solubility, decreased plasma protein binding, and cellular toxicity [1–4]. Molecular modelling and 
NMR studies have generated proposals on the mode of inclusion of the drug molecule by  
β-cyclodextrins [5,6] or their derivatives [7,8], including heptakis-(2,3,6-tri-O-methyl)-β-cyclodextrin 
or trimethyl-β-cyclodextrin, denoted as TRIMEB [9]. 
Midazolam is a preoperative anesthetic, belonging to a class of imidazobenzodiazepine compounds 
which is used as amnestics, hypnotics, anticonvulsants, and skeletal muscle relaxants [10] to further 
intensify the physiological repressive mechanisms mediated by γ-aminobutyric acid, the most common 
inhibitory neurotransmitter in the brain [11,12]. At acidic pH, midazolam exists over 90% in the  
open-ring (OR) and only 10% in the closed-ring (CR) form, reaching the equilibrium in the pH range 
2.3–4.0 [13,14]. It is believed that the possible mechanism of the OR-to-CR conversion could be 
achieved via the ionized transition state (TS) intermediate by the simultaneous transfer of a hydrogen 
atom and the N=C bond formation [15]. 
At physiological pH, at least 99% of the mixture is presented mostly as CR form of this chemical 
compound, and it is also assumed that only this form of the benzodiazepines is pharmacologically 
active [16]. Usually, the OR form is produced in solution during the midazolam degradation revealing 
the dissimilarity in the photostability of this compound at different pH [14], which contributes to the 
overall aqueous solubility of the drug [17]. 
Previously, midazolam has been solubilized with various cyclodextrin derivatives, including 
hydroxypropyl-, sulfobutyl-, and randomly methylated modifications of β-cyclodextrin [15,18]. 
However, the overall complexation efficacy for cyclodextrins is frequently low in order to solubilize 
even small amounts of any given benzodiazepine drug [15]. 
Presently, there are no data theoretically or experimentally available on the interaction between 
different forms of midazolam and TRIMEB to assess the complexation rate and toxicity considering 
both drug ionization and solubilisation at different pH values. Therefore, the prime objective of the 
study was to investigate the ionization profiles and inclusion mechanisms of the different forms of 
midazolam bound to TRIMEB in conjunction with an assessment of the midazolam-TRIMEB cellular 
toxicity to diminish possible adverse effects. 
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2. Results and Discussion 
The aqueous solubility of midazolam plays an important role in the supramolecular complexation 
with water-soluble cyclodextrins and depends on the imidazobenzodiazepine ring opening, which is a 
fully reversible process, and the ionization of the drug molecule [15]. Therefore, the total charges were 
assessed from the acid dissociation constant determined for different forms of midazolam as depicted 
in Figure 1. Firstly, predicted negative decimal logarithm of acid dissociation constant for the nitrogen 
atom in position 1 (N-1) of OR (݌ܭ௔ைோ(pred)), CR (݌ܭ௔஼ோ(pred)), and degree of dissociation for these 
forms of midazolam (Figure 1A) were calculated by using MarvinSketch software (ChemAxon, 
Budapest, Hungary). The net charges for midazolam forms at different pH were calculated from the 
Henderson-Hasselbalch equation [19] as follows: 
݌ܪ = ݌ܭ௔ + ݈݋݃
ߙ
1 − ߙ (1)
This equation could be rewritten to solve for α: 
ߙ = 110௣௄௔ି௣ு + 1 (2)
where ݌ܭ௔ is the negative decimal logarithm of acid dissociation constant and ߙ  is the degree of 
dissociation (Supplementary material 1). The Equations (1) and (2) were implemented considering the 
charge-contributing functional groups for predicting molecular macrospecies distribution (88% for OR 
and 86% for CR) at physiological pH. 
Figure 1. Calculated and experimentally derived degree of dissociation (A) denoted as α 
with ionic charge distribution (B) for the open-ring (OR) or closed-ring (CR) form of 
midazolam at different pH values according to Equations (1) and (2). 
 
It was already experimentally determined for benzodiazepines that the positively charged N-1 atom 
(݌ܭ௔ைோ(exp ) = 7.0, ݌ܭ௔ைோ(pred ) = 8.52) is affected by the pH-dependent reaction. Hence, the 
diazepine ring of 1,4-benzodiazepine moiety was formed with ݌ܭ௔஼ோ(exp)  of 2.4 [15,20] and 
݌ܭ௔஼ோ(pred) of 3.48. In addition, the basic nitrogen in position 2 of the imidazole ring, which belongs 
to the imidazobenzodiazepine moiety, allows the active elements of midazolam to form water-soluble 
salts with acids [21]. The imidazole ring of midazolam also accounts for its stability in solution and 
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rapid metabolism [22]. Consequently, the calculated net charges for both molecular forms were found 
to be positive (+0.9) for the OR form of midazolam and benzodiazepines (+0.3) or neutral for the CR 
form at physiological pH (Figure 1B) and Supplementary material 2. 
To further investigate the aqueous solubility, a restricted Hartree-Fock calculation with the 6-31G 
level of theory was performed using Pulay DIIS with geometric direct optimization to evaluate the free 
energy of solvation for the OR and CR forms of midazolam as shown in Figure 2A. In agreement with 
the experimental data that the aqueous solubility of midazolam at high pH defines by the formation of 
uncharged and lipophilic CR form [14], our calculations demonstrate that this structure has also been 
found to be less water-soluble because of higher lipophilicity ( ܥ݈݋݃ܲ  = 3.97), lower solvent 
excluded/accessible surface areas (SES = 278.56 Å2 and SAS = 518.59 Å2) and solvation energy 
(߂ܩ௦௢௟௩஼ோ = −9.98 kcal·mol−1) compared to the OR form of midazolam with the SES (SAS) value of 
296.68 (548.07) Å2, ܥ݈݋݃ܲ  (ionic species) of 0.08, and ߂ܩ௦௢௟௩ைோ 	 of −67.01 kcal·mol−1. For the  
OR/CR-TRIMEB inclusion complex, the optimal pH value to be easily dissolved is in the range from 
3.5 to 3.7, which might imply some difficulties on its intravenous applications (unpublished data). 
Moreover, the further pH elevation in the solution (up to 7.0) might increase the risk of a suspension at 
physiological pH or even precipitate formation at basic pH value.  
Figure 2. Thermodynamic cycle to evaluate the free energy of solvation (߂ܩ௦௢௟௩ைோ 	and 
߂ܩ௦௢௟௩஼ோ ) for midazolam open-ring (OR) and closed-ring (CR) forms (A) and reversible  
pH-dependent OR-to-CR conversion reaction (B) occurring through the formation of the 
ionized transition state intermediate (TS). 
 
The complexation of midazolam in the OR, TS, and CR forms with TRIMEB for controlled drug 
delivery and sustained release have been also examined to assess its mechanism and estimate the 
effects involved in the simultaneous transfer of a hydrogen atom and C=N bond formation (Figure 2B). 
Given that methods like AutoDock have a typical error of ±2 kcal·mol−1, which might produce a huge 
deviation of ߂ܩ௕௜௡ௗ and ܭ௕  for the investigated compound [23], the midazolam-cyclodextrin 
complexes, including OR-TRIMEB, TS-TRIMEB, and CR-TRIMEB, were subjected to the molecular 
docking with the subsequent data collection for analysis from three different experiments (Supplementary 
A B
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material 3). The ionized TS intermediate used in the docking studies is only a rough representation of 
the “real” TS structure; therefore, the energy calculated for this species is quite approximate. 
The molecular docking procedure as rigid-flexible approach using the Lamarckian genetic 
algorithm was already reported in various molecular docking studies as an efficient method to 
investigate ligand-cyclodextrin complexation mechanism [24–26]. On the other hand, the important 
guest-induced conformational change of the TRIMEB pyranose ring affecting the cavity shape and rim 
size [27,28] is not considered using our docking methodology due to the host total rigidity. 
Furthermore, the other obstacle to produce accurate free energy of complexation might be linked to the 
limit of the molecular mechanics AMBER force-field implemented in the AutoDock technique. 
Taken into account the modeled 1:1 stoichiometry of the open/closed-ring forms of midazolam and 
TRIMEB complex, it can be observed that the fluorine-containing phenyl ring of the OR structure, 
comprising big number of atoms ( ௔ܰ௧௦  = 26) and torsions ( ௧ܰ௢௥  = 5), as more flexible and  
chloride-containing diazepine ring in imidazobenzodiazepine moiety of TS ( ௔ܰ௧௦ = 27, ௧ܰ௢௥ = 1) and 
CR ( ௔ܰ௧௦ = 23, ௧ܰ௢௥ = 1) penetrate the TRIMEB cavity (Figure 3A–C). 
Figure 3. Predicted molecular docking modes with minimal Gibbs free energy of binding 
(߂ܩ௕௜௡ௗ) for open-ring (A), transition state intermediate (B) and closed-ring (C) form of 
midazolam complexed with TRIMEB. The molecular surface was reconstructed to 
visualize the binding cavity of uncharged trimethyl-β-cyclodextrin. The best binding poses 
with minimal ߂ܩ௕௜௡ௗ  values from three different molecular docking experiments are shown 
to reveal their conformational resemblances. Molecules are coloured according to their 
atom types. Hydrogen atoms are omitted for clarity. 
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In all cases, the degree of penetration for the guest molecule inside the host cavity is shallow. This 
might be caused by the partial occlusion of TRIMEB binding pocket with minimized states of  
methyl-glucose residues that under realistic conditions are expected to be quite mobile. In our docking 
experiments, the structure of TRIMEB represents “closed” spatial configuration when compared for 
instance with dimethyl-β-cyclodextrin or sulfobutyl-ether-β-cyclodextrin obtained by using several 
optimization steps in aqueous environment using the Merck molecular force-field (unpublished data). 
Van Oudtshoorn and co-authors previously reported that the structure of the “free” TRIMEB 
molecule as minimized form adopted a severely collapsed conformation where the hydrophobic cavity 
is minimal in the absence of hydrophobic guest [29]. Furthermore, this distorted conformation might 
also be related to the conformation observed for the unfunctionalized β-cyclodextrin, which is 
stabilized by multiple intramolecular C-H···O interactions ubiquitously presented in crystal structure 
of carbohydrates [30,31]. In reality, the solvation effects on the extra methyl groups of the uncharged 
TRIMEB molecule might lead to the cavity re-opening process resulting in the larger volume size of 
the binding crevice. 
Finally, using the AutoDock program, the calculations for open-ring form of midazolam-TRIMEB 
complex provided the best binding affinity to TRIMEB detected for OR with an average ߂ܩ௕௜௡ௗ value 
of −5.57 ± 0.02 kcal·mol−1 and an average ܭ௕ constant of 79.89 ± 2.706 μM, respectively. Moreover, 
the pH-dependent OR-to-CR transition via the TS form followed the unflavored energetic path during 
the TRIMEB complexation and characterized by a gradual elevation in ߂ܩ௕௜௡ௗ and ܭ௕ (Figure 4A,B 
and Table 1). By increasing the number of returned docking poses (ga_run = 100), it was also 
determined that the originally provided docked pose is still the likely bound pose and there are 99 
other possible host-guest configurations. Additionally, there are several commonly occurring docked 
poses formed during the clustering with the root-mean-square-deviation cut-off value of 2.0 Å and one 
of the most popular poses is the reported conformation with minimal ߂ܩ௕௜௡ௗ  value. In total, this  
low-energy conformation occurred in average 10, 36, and 34 times out of 100 for OR, TS, and CR 
forms, respectively (Supplementary material 3). 
Figure 4. Predicted Gibbs free energy of binding (߂ܩ௕௜௡ௗ ), ligand efficiency indexes 
(ܮܧ௟௜௚) (A) and equilibrium binding constants (ܭ௕/݌ܭ௕) (B) for open-ring (OR) transition 
state intermediate (TS), and closed-ring (CR) ring forms of midazolam complexed with 
TRIMEB. The ligand efficiency is defined as the calculated  ݌ܭ௕ divided by the number of 
heavy atoms in the ligand. The data represent means ± S.D. of three independent experiments. 
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Table 1. Statistics of molecular docking results for open-ring (OR), transition state (TS), 
and closed-ring (CR) forms of midazolam formulated with TRIMEB. 
Average Value SD 
Form ΔGbind * LElig Kb (μM) pKb ΔGbind * LElig Kb (μM) pKb 
OR −5.57 −0.21 79.89 4.09 0.02 0.001 2.706 0.015 
TS −5.15 −0.19 162.66 3.79 - - - - 
CR −4.66 −0.2 434.05 3.43 0.427 0.018 235.034 0.308 
Notes: *-Binding energies in kcal·mol−1; SD-Standard deviation. 
Taken into consideration the maximal clinical concentration for midazolam as 100 μg/L [32] and its 
relative inclusion content [w %], the CellTiter-Glo® (Promega, Madison, WI, USA) luminescent cell 
viability assay was used to determine the cytotoxicity of TRIMEB and OR/CR-TRIMEB on the cEND 
cells in either DMEM or in heat-inactivated human serum. Although the high purification of TRIMEB 
was achieved with significantly improved aqueous solubility (>50 g in 100 cm3 at 25 °C), the powder 
might incorporate the traces of undermethylated-β-cyclodextrin and residual β-cyclodextrin (<0.25%). 
Cell viability was assessed by the amount of adenosine triphosphate (ATP) produced by metabolically 
active cells. The released ATP converts the luciferin substrate to luciferin oxide, and released 
luminescence signals were recorded. The results of this assay showed the absence of a toxic effect of 
analysed substances in either DMEM or in human serum on cEND cells after 24 h of incubation. 
Overall, with increased time, no significant difference from the actual cell viability for TRIMEB and 
OR/CR-TRIMEB was revealed; their luminescence levels remained above the median toxic dose level 
(TD50). A significant reduction in luminescence activity was discovered after the treatment with 10% 
dimethyl sulfoxide (DMSO) served as a positive control indicating a massive cell death (Figure 5A,B). 
Figure 5. Cell viability assay is shown to measure the TRIMEB (A) and OR/CR-TRIMEB 
(B) toxic effects on the cEND cells over time (24 h). The luminescence is measured in 
percentage to a control group contained untreated cells. 10% solution of dimethyl sulfoxide 
(DMSO) was used as a positive control. The median toxic dose level is abbreviated as 
TD50. The thresholds are depicted as dashed lines. The data represent means ± S.D. of three 
independent experiments. 
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Figure 6. Predicted relative torsional (ܧ௧௢௥ ) energy (A,B) and bond length (ܧ௕௢௡ௗ )  
energy (C,D) for closed-ring (OR) and transition state (TS) forms of midazolam 
complexed with TRIMEB. A fit spline and smoothing curves are implemented to connect 
and fit the data points. All atoms comprising the torsional angle are depicted as grey 
spheres and measured bonds are illustrated as bold lines. 
 
 
To gain some insight into the binding characteristics of midazolam as unionized closed-ring 
molecule with a single torsional angle (N1-C7-C1-C2 framework), the quantum chemical method was 
implemented to evaluate the torsional energy contribution to the complexation process as a repulsion 
force between the bonds of groups attached to a central rotating bond. In particular, the Hartree-Fock 
technique with the 6-31G level of theory was applied to set the dihedral N1-C7-C1-C2 angle from 
61.6° determined for the minimized ligand to 114.23° increments determined for the best docking 
pose. The angular rotation occurred in a clockwise direction to record the energy for each point in a 
vacuum environment. The relative ܧ௧௢௥ values for all the different conformations of CR (10 structures) 
were in the range from −0.624 to 0.377 kcal·mol−1 (rotation is free at room temperature) indicating 
energetically favored and unflavored planar positions of the fluorophenyl ring and imidazobenzodiazepine 
moiety at different angles. Finally, the ܧ௧௢௥  value of −0.25 kcal·mol−1 was estimated for the best 
docking pose with the minimal ߂ܩ௕௜௡ௗ parameter resulting in the molecular interface rotation to reach 
the lowest energy orientation in comparison to the minimized structure (Figure 6A). Additionally, the 
relative energy contribution for the positively charged TS intermediate in the course of the 
complexation was also evaluated as a function of the internal rotation around the same dihedral angle. 
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The TS torsional angle shifts from 42.42° to −154.49° with the total increase in the relative torsional 
energy (ܧ௧௢௥ = 9.21 kcal·mol−1). This increase in the ܧ௧௢௥ value might be due to the steric hindrance 
between the hydroxyl side chain moiety and the fluorophenyl ring (Figure 6B). While a negative shift 
of −196.91° requiring an anticlockwise rotation prevails in the transition state as antiperiplanar or 
gauche-conformation, the increase in total angular shift between the same molecular parts was about 
+52.63° for OR corresponding to a positive anticlinal arrangement. Moreover, the intramolecular  
C7-C1 bond of CR was extended by 0.011 Å for the constrained bond length in the range from 1.484 
to 1.495 Å, and a decrease in the bond length energy (ܧ௕௢௡ௗ = −0.08 kcal·mol−1) was also observed 
(Figure 6C). Conversely, the C7-C1 bond distance in the TS structure was diminished by 0.024 Å from 
1.552 to 1.528 Å with a negative bond length energy of −0.53 kcal·mol−1 (Figure 6D). Consequently, 
the TS bond compression facilitated the simultaneous transfer of a hydrogen atom and N1C7 double 
bond formation along with its influence on the fluorophenyl ring rotation. 
3. Experimental Section 
The pure forms of TRIMEB (98% of purity) and midazolam-TRIMEB complex (OR/CR-TRIMEB) 
with 18.2% [w %] midazolam relative content to OR (22%) and CR (78%) fractions were prepared 
according to the following procedure: anhydrous β-CD (6.0 g, Sigma-Aldrich Co., St. Louis, MO, 
USA) was dissolved in dry dimethylformamide (50 mL). Sodium hydride (8.2 g) was added, and the 
mixture was stirred at room temperature for 20 min. The jelly-like mixture was cooled to 0 °C and 
treated portionwise with methyl iodide (43.6 mL) over a period of 30 min; the insoluble materials went 
into solution. The solution was stirred at room temperature for 24 h, cooled and the excess of sodium 
hydride was decomposed by the addition of methanol (25 mL). Finally, a white, amorphous solid 
powder of TRIMEB was obtained by hydrolysation and acetylation under conventional conditions for 
6.45 min at room temperature [33]. 
TRIMEB (10.77 g, 7.5 mM) was dissolved in 80 mL of distilled water. Midazolam (2.45 g, 7.5 mM) 
was added to the TRIMEB solution. The resulting suspension was stirred, and the pH value of the 
mixture was adjusted to 3.2 by adding 0.5 M hydrochloric acid (10.5 mL). The clear solution was 
stirred for 10 min and filtered through a hydrophilic polyvinylidene fluoride filter with 0.45 μm pore 
size. Subsequently, the final solution was frozen and lyophilized. 
An Agilent 8453 Diode Array Spectrophotometer was used for UV-Vis spectroscopic quantification 
of the drug substance within the complex in a quartz cuvette of 1 cm path length (Figure 7A,B). 
The two-dimensional coordinates of heptakis-(2,3,6-tri-O-methyl)-β-cyclodextrin (Figure 8A) or 
TRIMEB (CAS No. 55216-11-0) and the closed-ring form of midazolam (CID: 4192) were retrieved from 
the Chemical Book and PubChem servers, converted into the energetically minimized three-dimensional 
models (Figure 8B) using MarvinSketch software (ChemAxon, Budapest, Hungary).  
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Figure 7. UV-Vis spectrum of midazolam as OR/CR mixture based on the absorbance 
peak found at wavelength 220 nm (A). Midazolam aqueous solution is examined in 50% of 
ethanol at a pH level of 3.0. The absorbance is measured in arbitrary units, which are 
abbreviated as a.u. The linear calibration curve was fitted to the experimental absorbance 
data (B). 
(A) (B) 
Figure 8. Two- (A) and three-dimensional (B) representation of the heptakis-(2,3,6-tri-O-
methyl)-β-cyclodextrin (TRIMEB) structure. The 3D model is rendered as ball-and-stick 
and coloured according to atom type without hydrogens to enhance clarity. 
 
The same program was implemented to build the OR form and ionized TS intermediate, to perform 
their energy minimization and predict the calculated octanol-water partitioning coefficient (ܥ݈݋݃ܲ) 
with a weighted method as the default option and ion (Cl−, Na+, and K+) concentration of  
0.1 mol·dm−3. Rigid-flexible molecular docking was applied to the centre of the cyclodextrin molecule 
using Cartesian coordinates: x = −0.78 Å; y = −0.17 Å; and z = 0.0 Å. AutoDock v.4.2.5.1 was used in 
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term. The docking grid with a dimension size of 30 Å × 30 Å × 30 Å was used in the study. The grid 
spacing of 0.375 Å was used to create the AutoDock grid maps. For each compound, a number of 
standard genetic algorithm dockings (ga_run) was set to 100. The authors used the default settings 
within AutoDock and AutoGrid. The host and guest structure preparations for molecular docking 
included Gasteiger partial charges assignment [34] and rotatable bonds definition. The docking output 
results were represented by the docking scores as the estimated Gibbs free energy of binding (߂ܩ௕௜௡ௗ) 
and were further converted to the predicted equilibrium binding constants (ܭ௕) or ݌ܭ௕ values (negative 
decimal logarithm of ܭ௕). Estimated ߂ܩ௕௜௡ௗ and ܭ௕ parameters for the docked poses were calculated 
using the equations shown below: 
߂ܩ௕௜௡ௗ = ܧ௜௡௧௘௥ + ܧ௜௡௧௘௥௡௔௟ + ܧ௧௢௥ − ܧ௨௡௕௢௨௡ௗ (3)
ܧ௜௡௧௘௥ = ܧ௩ௗ௪ + ܧ௛௕ + ܧௗ௘௦௢௟௩+ ܧ௘௟௘௖௧ (4)
ܭ௕ = ݁ݔ݌
߂ܩ௕௜௡ௗ
ܴܶ  (5)
where ܧ௜௡௧௘௥  and ܧ௜௡௧௘௥௡௔௟  are the final intermolecular and total internal energies;ܧ௩ௗ௪_௛௕_ௗ௘௦௢௟௩  
corresponds to the sum of the energies of van der Waals (vdw), hydrogen bond (hb), and desolvation 
(desolv) terms; ܧ௘௟௘௖௧ is the electrostatic energy; ܧ௧௢௥ and ܧ௨௡௕௢௨௡ௗ are the torsional free and unbound 
system’s energies; R (gas constant) is 1.98 cal(mol·K)−1, and T (room temperature) is 298.15 Kelvin, 
respectively. The solvent excluded surface (SES) area and solvent accessible surface (SAS) area were 
calculated by the MGLTools program (Scripps Research Institute, San Diego, CA, USA); the python 
script (summarize_results4.py) was used to analyze and summarize the AutoDock results. A ligand 
efficiency index (ܮܧ௟௜௚) was computed as a parameter recently introduced for selection of useful lead 
molecules according to their binding energy per atom [35,36] using the following equation: 
ܮܧ௟௜௚ =
߂ܩ௕௜௡ௗ
௔ܰ௧௦
 (6)
where ߂ܩ௕௜௡ௗ	is the Gibbs free energy of binding and ௔ܰ௧௦ is the number of heavy atoms. 
To determine the cell viability for the pure TRIMEB structure and OR/CR-TRIMEB complex, the 
immortalized microvascular endothelial (cEND) cells of murine origin [37–39] were seeded in 96-well 
plate and grown to 90% of confluency in Dulbecco’s Modified Eagles Medium (DMEM) containing 
10% fetal calf serum (FCS), 50 U/mL penicillin/streptomycin, and 1% L-glutamine. Once confluent, 
cells were forced to differentiate in 1% serum-stripped fetal calf serum (ssFCS) for two days. Next, 
cells were incubated with analyzed substances in final concentrations of 40 µg/L–40 mg/L (TRIMEB) 
and 50 µg/L–50 mg/L (OR/CR-TRIMEB) for 24 h at 37 °C. Afterwards, cell viability was assessed 
using the CellTiter-Glo® (Promega, Madison, WI, USA) luminescent cell viability assay kit according 
to the manufacturer’s recommendation. Briefly, the test compound and controls were added to the cells 
in either DMEM or in heat-inactivated (56 °C for 30 min) human serum and the cells were further 
incubated for 30 min at room temperature, which after the CellTiter-Glo® solution was added. Cell 
lysis was achieved for 2 min with shaking followed by 10 min of equilibration at room temperature. 
Luminescence was assayed using the Tecan GENios Microplate Reader (MTX Lab Systems, Inc., 
Vienna, VA, USA). The restricted Hartree-Fock single-point energy calculations were performed with 
Pulay DIIS model and geometric direct optimization as implemented in the Spartan software 
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(Wavefunction, Inc., Irvine, CA, USA) in order to calculate the free energy of solvation for OR/CR 
forms of midazolam (߂ܩ௦௢௟௩ைோ , ߂ܩ௦௢௟௩஼ோ ), relative torsional (ܧ௧௢௥), and bond length (ܧ௕௢௡ௗ ) energies. 
Relative torsional energy ܧ௧௢௥ was calculated from a truncated Fourier series using the equation in the 
form shown below: 
ܧ௧௢௥ = 	݇௧௢௥ଵ ቀ1 − ܿ݋ݏ൫߱ − ߱௘௤൯ቁ + ݇௧௢௥ଶ ቀ1 − ܿ݋ݏ2൫߱ − ߱௘௤൯ቁ
+ ݇௧௢௥ଷ ቀ1 − ܿ݋ݏ3൫߱ − ߱௘௤൯ቁ 
(7)
where ߱௘௤  is the ideal dihedral angle and ݇௧௢௥ଵ , ݇௧௢௥ଶ , and ݇௧௢௥ଷ  are the torsional constants for  
one-fold, two-fold, and three-fold rotational barrier. Fourier series were implemented to solve 
nonlinear least squares curve-fitting via the oscillating function. Bond length energy (stretching and 
compression) based on Hook’s law was computed as follows:  
ܧ௕௢௡ௗ = ෍ܾ݋݊݀ݏ ݇௕(ݎ − ݎ଴)ଶ (8)
where ݇௕  is the stiffness factor while ݎ  and ݎ଴  values define the bond equilibrium length for each 
bonded atoms based on their types. All molecular rendering scenes and graphic representations were 
prepared by the Persistence of Vision Raytracer (POV-Ray) module (Persistence of Vision Pty. Ltd., 
Williamstown, Australia) included in the Chimera version 1.6.2 software (Resource for Biocomputing, 
Visualization, and Informatics, San Francisco, CA, USA), ChemBioDraw® Ultra 14 (PekinElmer, 
Waltham, MA, USA), QuteMol v.0.4.1 [40], Wolfram Mathematica 10 (The Wolfram Centre, Long 
Hanborough, UK), and GraphPad Prism v.4 for Windows software (GraphPad Software, Inc.,  
San Diego, CA, USA). 
4. Conclusions 
In the current study, we report results that show that the total net charges have a tendency to be 
cationic for OR and neutral for CR at physiological pH, influencing their complexation with the 
TRIMEB molecule. A lower degree of aqueous solubility was found for the CR structure with its 
higher solvation energy (߂ܩ௦௢௟௩஼ோ 	= −9.98 kcal·mol−1) than for the more hydrophilic OR form with a 
minimal ߂ܩ௦௢௟௩ைோ 	of −67.01 kcal·mol−1 during the OR-to-CR conversion that occurred through the 
formation of ionized TS intermediate. The absence of TRIMEB and OR/CR-TRIMEB toxicity in the 
cEND cells after 24 h of incubation (in either Dulbecco’s Modified Eagles Medium or heat-inactivated 
human serum) was confirmed by a CellTiter-Glo® (Promega) luminescent cell viability assay. Despite 
the lack of cellular toxicity, the native pH value required to dissolve the OR/CR-TRIMEB complex is 
in the range of 3.5–3.7, limiting its usage to clinical applications. The molecular docking method 
detected that the more flexible OR form ( ௧ܰ௢௥ = 5) of midazolam may serve as a better binder to 
trimethyl-β-cyclodextrin with the fluorophenyl ring introduced inside the amphiphilic cavity  
of the TRIMEB. The optimal OR binding affinity was verified by a minimal ߂ܩ௕௜௡ௗ value of  
−5.57 ± 0.02 kcal·mol−1, an equilibrium binding constant (ܭ௕) of 79.89 ± 2.706 μM, and a ligand 
efficiency index (ܮܧ௟௜௚) of −0.21 ± 0.001. A decrease in the torsional energy (ܧ௧௢௥ = −0.25 kcal·mol−1) 
for the active CR form was detected in order to reach the lowest energy orientation during the 
conformational sampling. Therefore, it is important to improve the clinical applications of midazolam 
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via its complexation with trimethyl-β-cyclodextrin in order to increase its overall aqueous solubility 
concerning the different forms and ionization states of this anaesthetic. 
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